October to December
- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -6.8 (-5.7), corresponding to earnings per share of SEK -0.11 (-0.09)
- Cash flow after financing activities amounted to MSEK -5.7 (-6.8)
- Cash amounted to MSEK 17.8, compared to MSEK 45.3 on 31 December 2021
January to December
- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -26.6 (-26.7), corresponding to earnings per share of SEK -0.44 (-0.56)
- Cash flow after financing activities amounted to MSEK -27.5 (+21.1)
Significant events during January – December
- In January 2022, warrants corresponding to a dilution of 0.2% of the number of outstanding shares were deregistered;
- In February 2022, the first trial person was enrolled in PHSU05 (ensereptide);
- The recruitment target for the study was achieved according to plan in March;
- At the AGM in May, Marianne Dicander Alexandersson was elected new chairman of the board. Also, Candice Jung was elected new member of the board;
- In June 2022, the last clinic visit in PHSU05 occurred (ensereptide);
- In August 2022, the company received a granted patent in the European Union for the use of the candidate drug ropocamptide (LL-37) for the treatment of chronic wounds;
- In November 2022, it was announced that results from PHSU05 are expected in April 2023, where the lack of specialized staff and equipment is the reason for the slight delay.
Events after the reporting period
- In February 2023, the milestone Clean file was reached in PHSU05, and thereby the probability is high that the outcome of the study can be concluded and communicated in April 2023.
” The clinical part of the trial was completed in June 2022, and work on the histopathological analysis is in a final phase.”
Jonas Ekblom, President and CEO of Promore Pharma